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Abstract It is known that Myc regulates the expression of
TERT, the telomerase catalytic subunit gene, by binding to E
box. Here we show that another E box-binding protein,
upstream stimulatory factor (USF), also regulates TERT
expression. Specifically, the N-terminally truncated form of
USF2 is present in telomerase-negative/resting human lympho-
cytes, but not in telomerase-positive/phytohemagglutinin-acti-
vated lymphocytes. In electrophoretic mobility shift assay, both
full-length and truncated USF2s bound to the TERT E box. In
a transient expression assay, the truncated USF had a
dominant-negative effect on both exogenous full-length USF
and endogenous positive regulators for activating TERT
expression. These results suggest that the differential abundance
of truncated USF2 may regulate telomerase activity during
lymphocyte activation. ) 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Telomerase is a specialized reverse transcriptase that com-
pensates for the telomere length reduction caused by the end
replication problem (for recent review, see [1]). It is active in
germ cells and 90% of cancer cells, but not in most normal
somatic cells [2]. Two components, telomerase reverse tran-
scriptase (TERT) and telomerase RNA (TR), are essential for
the enzymatic activity measured in vitro. TR is expressed in a
relatively wide range of cells, regardless of the presence or
absence of telomerase activity. It is thought that the expres-
sion level of TERT primarily determines the activity [3^8].
Several transcription factors, including Myc, Sp1, ER (es-
trogen receptor), MZF-2, and E2F-1, have been proposed to
regulate TERT expression [9^15]. Among them, TERT acti-
vation by Myc has been well demonstrated [9,11,16,17]. Myc
belongs to the bHLH-zip (basic helix-loop-helix zipper) tran-
scription factor family (reviewed in [18]). Myc, as well as other
members of this family, forms a heterodimer with Max to
bind to a consensus sequence called E box (5P-CACGTG-
3P), thereby activating gene expression. Because Max is ubiq-
uitously present in cells, the Myc^Max activity is largely regu-
lated by the amount of Myc. Myc is a short-lived protein, and
its abundance is correlated with the cell proliferation rate.
Therefore, Myc is an attractive candidate for regulating
TERT expression, which is known to be high in proliferating
cells [19].
Upstream stimulatory factor (USF) is another bHLH-zip
protein that binds to E box. Two structurally and functionally
related proteins derived from distinct genes, USF1 and USF2,
are known [20]. In contrast to Myc, USF1 and USF2 are
expressed ubiquitously in di¡erent types of cells. Accordingly,
it was initially postulated that USF1 and USF2 are involved
in regulating the expression of housekeeping genes [21]. How-
ever, there is evidence that USF1 and USF2 are also involved
in tissue-speci¢c and hormone- and nutrition-induced gene
expression ([22] and references therein). It is not understood
how ubiquitously expressed factors contribute to these con-
trolled processes.
Several variant forms of USF1 and USF2 have been iden-
ti¢ed: these are derived from alternative splicing, and prob-
ably from alternative choice of the initiation codon or post-
translational modi¢cation [23,24]. In vitro, USF1 and USF2
form both homo- and heterodimers at similar e⁄ciencies, but
in vivo they prefer to form heterodimers rather than homo-
dimers [25]. Di¡erent types of USF1^USF2 heterodimers were
found, depending on the di¡erent combinations of USF1 and
USF2 variant forms.
Most studies that elucidated the transcriptional control of
hTERT have been conducted using cell lines, and we know
very little about how hTERT expression is controlled in nor-
mal cells. hTERT expression and telomerase activity are
strictly regulated during proliferation and di¡erentiation of
normal human cells. For example, resting human lympho-
cytes, which are negative for telomerase activity, induce
hTERT expression and become telomerase-positive upon
being activated by a variety of stimuli, such as mitogenic
lectin PHA (phytohemagglutinin). We do not know what
transcriptional factors are involved in this regulated process.
In this study, we examined whether USF proteins are involved
0014-5793 / 02 / $22.00 K 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 7 5 7 - 6
*Corresponding author. Fax: (81)-75-753 4197.
E-mail address: ¢shikaw@lif.kyoto-u.ac.jp (F. Ishikawa).
FEBS 26113 27-5-02
FEBS 26113FEBS Letters 520 (2002) 40^46
in the control of hTERT expression. The results revealed that
di¡erential abundance of variant forms of USF2 may contrib-
ute to hTERT induction in activated lymphocytes.
2. Materials and methods
2.1. Cell culture
Human normal peripheral blood mononuclear cells (PBMCs) were
isolated from healthy volunteers by Ficoll^Conray density gradient
centrifugation. Cells were initially cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
for 1 h in a 37‡C, 5% CO2 humidi¢ed incubator. Non-adherent cells,
most of which do not contain monocyte/macrophages, were collected
and washed twice with RPMI 1640 medium. Fractions of T cells and
B cells were analyzed by FACS using magnetic beads bound to mono-
clonal antibodies against CD2/CD19. Cells were resuspended and cul-
tured in RPMI 1640/10% FBS containing 3 Wg/ml PHA (Gibco).
HEK293, KMST6, SUSM1, WI38RA were cultured in Dulbecco’s
modi¢ed Eagle medium supplemented with 10% FBS.
2.2. Stretch PCR assay
Cellular telomerase activity was measured by stretch PCR assay as
described [26].
2.3. Nuclear extract (NE) preparation
NEs of cells were prepared by the modi¢ed Dignam method [27]. In
brief, cells were washed with phosphate-bu¡ered saline twice, and
suspended in 400 Wl of bu¡er A (10 mM HEPES (pH 7.9), 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT),
0.5 mM PMSF). After 15 min of incubation on ice, cells were homog-
enized by passing them through a 23-gauge needle, and the sample
was centrifuged for 1 min at 10 000 rpm. Nuclei pellets were resus-
pended in and salt-extracted with 50 Wl of bu¡er B (20 mM HEPES
(pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
1 mM PMSF), and then incubated on ice for 30 min. The supernatant
was collected, dialyzed against bu¡er C (20 mM HEPES (pH 7.9),
20% glycerol, 0.1 M KCl, 0.2 mM EDTA, 1 mM DTT) and used as
NEs.
2.4. Electrophoretic mobility shift assays (EMSAs)
NE (5 Wg/reaction for lymphocyte NE and 1 Wg/reaction for 293 cell
NE) was incubated with 30 000 cpm of end-labeled oligonucleotide
probes in the presence of 2 Wg poly(dI-dC) (Amersham Pharmacia
Biotech) in a ¢nal volume of 25 Wl bu¡er containing 50 mM KCl,
50 mM NaCl, 20 mM HEPES (pH 7.5), 5 mM DTT, 5 mM MgCl2,
and 12% glycerol. For competition assays, 100-fold molar excess of
oligonucleotide was used in the binding reaction. For supershift as-
says, NEs initially preincubated with 1 Wl of polyclonal antisera for 60
min were used for EMSA. The used polyclonal antibodies were: anti-
c-Myc (sc-42X, sc-764X), anti-Max (sc-765X), anti-USF-1 (sc-229X),
and anti-USF-2 (sc-861X, sc-862X) (Santa Cruz). Binding reactions
were resolved by 5% polyacrylamide gel electrophoresis (PAGE) at
4‡C.
2.5. Western blotting
Cell extracts were prepared by extracting lymphocyte cells with the
lysis bu¡er (50 mM Tris^HCl, 1% NP40, 150 mM NaCl, 50 mM NaF,
1 mM Na3VO4, 5 mM EDTA, 1 mM PMSF, 3 mM L-glycerophos-
phate, 1 mM DTT, 1Ucomplete cocktail protease inhibitor (Roche)).
Western blotting was performed using an enhanced chemilumines-
cence kit (Amersham Pharmacia Biotech). NEs containing 50 Wg of
protein were analyzed using polyclonal antibodies (1:100 dilution).
2.6. Plasmid construction
The hTERT promoter region (3232 to +98 nucleotides from the
transcription start site) was inserted into the pGL3-promoter vector
(Promega) to produce the hTERT-luciferase reporter plasmid. cDNAs
encoding mini-USF1 (v1^163) and mini-USF2 (v1^198) were pro-
duced by PCR. The nucleotide sequences of all plasmid constructs
were con¢rmed.
2.7. Promoter activity assays
293, KMST6, WI38RA and SUSM1 cells were plated 24 h prior to
transfection. DNA transfection was performed using FuGENETM6
transfection reagent (Boehringer Mannheim) or lipofectamine reagent
(Life Technologies). At 40^48 h after transfection, cell NEs were pre-
pared, and luciferase assays were performed using the dual luciferase
assay system (Promega). The transfection e⁄ciency was normalized by
that of the co-transfected pRL-TK vector (Promega). All experiments
were performed in triplicate.
3. Results
It is known that hTERT expression and telomerase activity
are induced in normal human lymphocytes upon activation by
PHA [28,29]. We chose this system to study the molecular
mechanism of hTERT induction in normal somatic cells. Hu-
man PBMCs were isolated from healthy volunteers by Ficoll^
Conray density gradient centrifugation. Monocyte/macro-
phages were removed by collecting non-adherent cells. The
thus-prepared cells typically consisted of 70^85% T cells,
10^20% B cells. Cells were treated with 3 Wg/ml PHA, cultured
and harvested. As reported previously, telomerase activity,
which was very low in unstimulated lymphocytes, became
noticeably induced on day 1.5, and high on days 3.5 and
5.0 in PHA-treated lymphocytes. hTERT expression was
hardly observed in unstimulated lymphocytes, but was signi¢-
cantly induced in lymphocytes activated by PHA with kinetics
similar to that of telomerase activity. hTERC, the gene encod-
ing human TR, was already expressed in unstimulated cells,
and the expression level was largely unchanged during PHA
stimulation. Therefore, as previously reported, it was highly
possible that PHA induced telomerase activity in lymphocytes
by activating hTERT expression. This idea is further sup-
ported by a recent result that stable expression of ectopic
TERT results in the extension of the replicative life span in
lymphocytes [30]. In the following experiments, we used un-
stimulated lymphocytes (resting lymphocytes) and activated
lymphocytes that were obtained after 3 days incubation with
PHA.
3.1. USF1 and USF2 bind to hTERT E boxes
It is well established that the two E boxes present in the
hTERT promoter (at 3210 bp and 334 bp from the trans-
lation initiation site, hereafter called the upstream and down-
stream E box, respectively, Fig. 1A) play a pivotal role in the
regulation of hTERT expression by Myc [9,11]. To examine
whether these E boxes are also involved in the hTERT induc-
tion by PHA in normal human lymphocytes, we performed
EMSA using two oligonucleotide DNA probes containing the
upstream or downstream E box (upstream and downstream
probes, respectively, Fig. 1A). The upstream and downstream
probes had the same nucleotide length. In the absence of NEs,
no shifted band was observed (data not shown, and see Fig.
2A, lane 7). Both upstream (Fig. 1B, lanes 1^6) and down-
stream probes (Fig. 1B, lanes 7^10) produced retarded bands
upon incubation with NEs from resting and activated lym-
phocytes. Resting cell NEs produced two di¡erent bands:
slow-migrating (thin arrows) and fast-migrating (thick arrows)
bands. The fast-migrating band had a signi¢cantly greater
abundance than the slow-migrating band. Interestingly, only
a single retarded band was produced by activated cell NEs,
which migrated to the same position as that of the slow-mi-
grating band produced by resting cell NEs. These probe^pro-
tein complexes were speci¢c since they were not detected when
a 100-fold molar excess of the cognate probe was added (lanes
3, 6, 8 and 10). This competition was not observed when
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mutant competitors that contain TTTGTG instead of
CACGTG were used, further substantiating that the complex
formation depends on the authentic E box sequence (lanes 2
and 5). These results indicated that resting cell NEs exhibited
an additional binding activity to the E box probes compared
to activated cell NEs. To examine whether Myc is involved in
the formation of these complexes, three independent antibod-
ies against Myc or Max were included in the binding reac-
tions. However, no supershift of the band mobility was ob-
served, suggesting that Myc is not responsible for the complex
formation (data not shown).
We then investigated whether USF is involved in the DNA^
protein complex formation. Fig. 2A shows the results ob-
tained by EMSA using the downstream probe. The same re-
Fig. 1. Two E boxes in the hTERT promoter region and exon 1. A: Potential binding sites for transcription factors in the hTERT promoter re-
gion (upper panel) and the nucleotide sequences around the two E boxes. Numbers on the left refer to the distance from the translation initia-
tion site (marked by an arrow). The two E boxes are enclosed by boxes, and the oligonucleotide probes used in this study are shown. B:
EMSA using oligonucleotide probes containing the hTERT E box sequences. The upstream and downstream probes shown in (A) were used as
probes in EMSA using resting and activated lymphocyte NEs. Binding reaction was performed without (competitor 3) or with 100-fold molar
excess of cold wild-type oligonucleotides (W) or mutated (the E box sequence, CACGTG, was mutated to TTTGTG) versions of oligonucleoti-
des (M). Speci¢c DNA^protein complexes are indicated by thick and thin arrows. To di¡erentiate the two bands clearly, the electrophoresis
was carried out for an extended time, and the free probe run away from the gel. However, in a separate experiment, we con¢rmed that the re-
action took place under the condition that the free probe was present in excess of the DNA-binding activity (also see Fig. 2C).
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sults were obtained using the upstream probe (part of the
results is shown in Fig. 2C). Antibodies against the C-termi-
nus of USF1 (anti-U1-C) supershifted both the fast-migrating
band produced by resting cell NEs and the slow-migrating
band produced by activated cell NEs (lanes 2 and 5). Simi-
larly, antibodies against the C-terminus of USF2 (anti-U2-C)
changed the mobility of these two bands (lanes 3 and 6). In
this experiment, no slow-migrating band was observed in the
reaction with the resting cell NEs. These results suggested that
the complexes produced by the resting and activated lympho-
Fig. 2. USF1 and USF2 are responsible for the E box-binding activity present in lymphocyte extracts. A: Supershift assay of retarded bands
using anti-USF antibodies. EMSA was performed using the downstream E box oligonucleotide probe, and NEs derived from resting (Resting)
or activated (Activated) lymphocytes. NEs from 293 cells over-expressing full-length USF1 and USF2 simultaneously (U1+U2) or mock-trans-
fected (mock) were also used. To identify the protein contained in the complexes, antibodies indicated were added to the binding reaction and
the supershift of the electrophoretic mobility was monitored. The two retarded bands found in Fig. 1B are shown by thick and thin arrows. B:
Schematic structures of human full-length USF1 (hUSF1), USF2 (hUSF2), mini-USF1 and mini-USF2 [23]. Numbers show the amino acid po-
sitions. USR, USF-speci¢c region, and bHLH-zip, basic helix-loop-helix zipper. C: Supershift of retarded bands in EMSA using the upstream
E box probe. EMSA was performed using the upstream probe, as well as NEs from resting (Resting) and activated (Activated) lymphocytes,
and 293 cells mock-transfected (mock), over-expressing mini-USF2 (mini-U2), USF1+mini-USF2 (1+mini-U2), or USF2+mini-USF2 (2+mini-
U2). The antibodies indicated were added to the binding reaction and the supershift of the band mobility was monitored. Fast- and slow-mi-
grating bands produced by resting and activated cell NEs, respectively, are shown by thick and thin arrows. Because the transfected 293 cell
NEs contained signi¢cantly higher binding activities than those in the lymphocyte NEs, lanes 1^8 and lanes 9^18 were obtained after longer
and shorter exposures to X-ray ¢lms, respectively.
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cyte NEs contained both USF1 and USF2. To con¢rm this,
ectopically expressed USF proteins were examined in the same
EMSA. NEs from 293 cells simultaneously over-expressing
full-length USF1 and USF2 generated in the presence of the
downstream probe a band having exactly the same mobility as
those produced by the NEs from activated lymphocytes (lane
8). Because the band intensity was signi¢cantly higher than
that obtained by mock-transfected 293 cell NEs (lane 9), the
shifted band should be produced by ectopically expressed
USF1 and USF2. Accordingly, we concluded that the slow-
migrating band observed with activated lymphocyte NEs was
generated by the full-length USF1WUSF2 heterodimer.
We next examined the identity of the fast-migrating band
produced by the resting lymphocyte NEs. USF1 and USF2
share highly homologous C-terminal sequences that comprise
the bHLH-zip region, which is important for DNA-binding
and dimerization (Fig. 2B). Immediately upstream of this re-
gion is a short sequence conserved in USF proteins, called
USR (USF-speci¢c region). USR is essential for the transcrip-
tional activation activity of the protein [24]. The N-terminal
regions di¡er markedly between USF1 and USF2. It has been
suggested that smaller variants of USF1 and USF2 that con-
sist of USR+bHLH-zip but lack the N-terminal regions may
exist [23]. These putative variant forms are called mini-USF1
and mini-USF2, respectively.
To examine the possibility that mini-USF2 is involved in
the complex formation in resting lymphocyte NEs, antibodies
against the N-terminus of USF2 (anti-U2-N) were included in
the reaction (Fig. 2C). Fig. 2C shows the results obtained in
EMSA using the upstream probe. The same results were ob-
tained in EMSA using the downstream probe (data not
shown). Both fast- and slow-migrating bands generated by
resting and activated lymphocyte NEs, respectively, were sen-
sitive to the supershift by anti-USF1 C-terminus and anti-
USF2 C-terminus antibodies (lanes 2, 3, 6 and 7). Anti-U2-N
supershifted the slow-migrating band produced by activated
lymphocyte NEs, but not the fast-migrating band produced
by resting lymphocyte NEs (lanes 4 and 8). These results
suggested that the fast-migrating band does contain an epi-
tope reactive with anti-U2-C but not an epitope reactive with
anti-U2-N. One possible explanation for these results is that
the fast-migrating band consists of the N-terminally truncated
variant form of USF2, such as mini-USF2, instead of the full-
length USF2. To test this possibility, we over-expressed mini-
USF2, USF1+mini-USF2 and USF2+mini-USF2, individu-
ally in 293 cells, and the resultant cell NEs were used in
EMSA (lanes 9^18). Several shifted bands showing di¡erent
mobilities were observed in experiments using di¡erent NEs.
It is known that mini-USF2 forms a homodimer capable of
binding to DNA. Therefore, the fastest band found in the
experiment using 293 cells over-expressing mini-USF2 alone
most likely represented the mini-USF2Wmini-USF2WDNA com-
plex (lane 10). Indeed, anti-U2-C, but not anti-U2-N, super-
shifted this band (lanes 11 and 12). Accordingly, the addi-
tional fast-migrating bands observed in experiments using
293 cells over-expressing USF1+mini-USF2 or USF2+mini-
USF2 were attributed to USF1Wmini-USF2 and USF2Wmini-
USF2, respectively. Finally, the two bands that were produced
by 293 cells over-expressing USF2+mini-USF2 and sensitive
to the supershift by anti-U2-N antibodies were thought to
represent USF2WUSF2 (or USF1WUSF2) and USF2Wmini-
USF2. In these experiments, we found that the fast-migrating
band generated by the resting lymphocyte NEs showed a very
similar, if not identical, behavior with the band produced by
USF1Wmini-USF2: both showed similar mobilities, and were
resistant to the supershift by anti-U2-N antibodies. It was
therefore suggested that the binding activity present in resting
lymphocytes to the hTERT E box probe is attributed to the
heterodimer between USF1 and N-terminally truncated USF2
having a similar structure to mini-USF2.
3.2. N-terminally truncated USF2 is present in resting
lymphocytes and not in activated lymphocytes
The di¡erential usage of N-terminally truncated USF2 and
full-length USF2 between resting and activated lymphocytes
in binding to the hTERT E box sequence may be caused by
the di¡erential abundance of these two types of USF2 pro-
teins. Previously, it was described that variant USF proteins
exist di¡erentially in various cell types [25]. Full-length USF2,
identi¢ed by its mobility in SDS^PAGE and reactivity to both
anti-U2-N and anti-U2-C, was found in almost the same
abundance in both resting and activated lymphocytes (Fig.
3, marked by a closed circle). In contrast, mini-USF2, identi-
¢ed by its mobility and reactivity to anti-U2-C but not anti-
Fig. 3. N-terminally truncated form of USF2 is present in resting,
but not in activated lymphocytes. Crude cell extracts containing the
same amounts of protein derived from resting (Resting) and acti-
vated (Activated) lymphocytes, mock-transfected 293 cells (mock),
USF2-over-expressing 293 cells, and mini-USF2-over-expressing 293
cells were examined by Western analysis using anti-USF2 C-termi-
nus antibodies (anti-U2-C) or anti-USF2 N-terminus antibodies
(anti-U2-N). Relative amounts of protein in lymphocyte extracts
were ¢ve-fold larger than those in 293 cell extracts. Gels stained
with Coomassie brilliant blue (CBB) are also shown. A and B were
run in 10% and 15% SDS^PAGE, respectively. Closed and open
circles represent the full-length USF2 and the N-terminally trun-
cated USF2, respectively.
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U2-N, was detected in resting lymphocytes, but not in acti-
vated lymphocytes (marked by open circles). These results
indicated that mini-USF2 is present in resting lymphocytes,
and contributes to binding to the hTERT E box sequence.
3.3. mini-USF2 does not activate hTERT promoter on its own,
and shows a dominant-negative e¡ect on full-length USF2
To determine whether the N-terminally truncated form of
USF2 found in resting lymphocytes has any biological role in
hTERT expression, mini-USF2 was over-expressed, and its
e¡ect on a reporter plasmid containing the hTERT promo-
ter+luciferase chimeric gene was examined. First, we used 293
cells that are telomerase-positive and actively express the en-
dogenous TERT gene. Co-transfection of full-length USF1- or
USF2-expressing vector together with the reporter plasmid
resulted in an enhanced expression of the hTERT promoter
compared to that found in the absence of over-expressed
USF1 or USF2 (approximately two-fold) (Fig. 4A). This rel-
atively weak hTERT-inducing activity by over-expressed
USF1 and USF2 may be explained by the hypothesis that
293 cells have abundant endogenous positive regulators that
saturate the hTERT promoter activity (including USF1 and
USF2) (see below). When mini-USF1 or mini-USF2 was over-
expressed, the hTERT promoter activity was signi¢cantly low-
er compared to that in mock-expressing cells. This result is
most simply explained by the hypothesis that the introduced
hTERT promoter was activated by the endogenous full-length
USF1 and USF2, but this activation was inhibited by the
dominant-negative e¡ect of mini-USF1 and mini-USF2 (see
below).
Several cell lines and cancers are known to maintain telo-
meres independently of telomerase, and are collectively called
ALT (alternative lengthening of telomeres). ALT cells do not
express TERT, and presumably lack factors necessary for
TERT gene expression [31]. We thought that ALT cells might
re£ect the e¡ects in the promoter assay of exogenous trans-
factors more directly than telomerase-positive cells do, be-
cause the TERT promoter should not be saturated by the
weak endogenous activating activity. We then used KMST6
cells, an ALT cell line, in our promoter assay. Full-length
USF1 and USF2 activated the promoter activity at signi¢-
cantly higher levels (Fig. 4B, approximately 5.8- and 4.8-
fold, respectively) than that observed in 293 cells, as expected.
In contrast to 293 cells, mini-USF1 or mini-USF2 did not
inhibit the endogenous activity to activate the hTERT pro-
moter, suggesting that endogenous USF1 or USF2 is not
functional in terms of activating the hTERT promoter in
this cell line (Fig. 4C). Importantly, when full-length USF2
and mini-USF2 were simultaneously over-expressed, the tran-
scription activation by full-length USF2 alone was signi¢-
cantly inhibited by mini-USF2 (Fig. 4C). Similar results
were obtained using WI38RA and SUSM1 cells that are
also ALT cells. This result indicates that mini-USF2 has a
dominant-negative e¡ect on full-length USF2 in activating
the hTERT promoter.
4. Discussion
Because telomerase is active in proliferating cells including
activated lymphocytes [19], and Myc is induced immediately
after the addition of PHA to lymphocytes [32], it appears that
Myc is a good candidate for explaining the physiological con-
trol of TERT expression in these cells. However, the correla-
tion between Myc induction and TERT expression is not al-
ways observed. For example, primary human B lymphocytes
activated by Epstein^Barr virus actively proliferate, yet do not
show telomerase activity [33]. Papilloma virus E6 oncoprotein
is known to induce TERT expression and telomerase activity
[34]. However, correlation between the levels of Myc and
TERT expression was not observed in experiments using a
set of E6 mutants [35]. These results strongly suggest that in
addition to Myc, there is another pathway for controlling
TERT expression.
The presence of the N-terminally truncated form of USF2
has been originally suspected based on in vitro observation
[23]. However, the implication that mini-USF2 may be in-
volved in gene expression control in vivo is not unprece-
dented. DNA-binding activity to the PGHS-2 (prostaglandin
G/H synthetase-2) promoter, which was attributed to mini-
USF, was identi¢ed in bovine granulosa cells that were un-
stimulated by human chorionic gonadotropin (hCG), but not
in hCG-stimulated cells. It was therefore proposed that hCG
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Fig. 4. Luciferase promoter assay of hTERT. A: Plasmids over-expressing the indicated modulators were co-transfected into 293 cells with the
reporter plasmid containing the hTERT promoter3luciferase chimeric gene. Fold increases of luciferase activity compared to that in the mock-
transfected cells are indicated. Relative transcriptional activities of mock- and USF-transfected samples were evaluated using the Dunnet’s test.
A statistically signi¢cant di¡erence (P6 0.05) is indicated by an asterisk. B,C: Similar experiments were conducted in KMST6 cells using the
indicated modulators. The total amount of transfected DNA was the same in these experiments. When USF2 and mini-USF2 were simulta-
neously transfected, the same molar amount of each plasmid was used. A statistically signi¢cant di¡erence (P6 0.05) between values obtained
with the mock- and USF-transfected samples is indicated by an asterisk. Values obtained with the USF2- and USF2+mini-USF2-transfected
samples were statistically signi¢cant (P6 0.05) using the Student t-test (double asterisk).
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induces PGHS-2 by removing the negative regulator, mini-
USF2 [22]. In this study, we observed similar ¢ndings: the
DNA-binding activity attributed to the N-terminally trun-
cated form of USF2 was speci¢cally found in telomerase-neg-
ative resting lymphocytes, and not in telomerase-positive acti-
vated lymphocytes. Furthermore, using a transient expression
assay, we showed that mini-USF2 has a dominant-negative
e¡ect on full-length USF2 in activating the hTERT promoter.
These results support the idea that the di¡erential abundance
of variant forms of USF2 may control the hTERT promoter
during human lymphocyte activation.
Because USF and Myc bind to the same sequence (E box),
it appears that they should associate with a particular pro-
moter in a mutually exclusive manner. However, using the
chromatin immunoprecipitation assay, it was found that the
same E box sequence present in the CAD gene could be
bound to Myc and USF in vivo in a given population of cells
[36]. It is not known whether Myc and USF simultaneously
bind to a particular E box in a single DNA molecule. It is,
however, possible that a single E box sequentially associates
with Myc and USF, and binding to one factor augments the
e¡ect of the other factor. Therefore, we do not exclude the
possibility that Myc plays an important role in controlling
TERT expression. Rather, we propose that Myc and USF
coordinately regulate TERT expression. One attractive possi-
bility is that chromatin structures of the E box are ¢rst
opened by Myc, which is known to associate with histone
acetylase, and then the general transcription factor USF pro-
teins bind to the opened E box [18]. In this context, the USF
complexes containing the N-terminally truncated form of
USF2 may inhibit the association of the active USF complex
formed by the full-length USF proteins. This type of negative
regulator may be important in normal human cells in which
telomerase is known to be strictly regulated.
Acknowledgements: We are grateful to Dr. M. Sawadogo for human
USF1 cDNA, and Dr. S. Vaulont for human USF2 cDNA. The
excellent secretarial work of F. Nishizaki, K. Saito, K. Yokoyama
and A. Orii is acknowledged. This work was supported by a grant-
in-aid from the Organization for Pharmaceutical Safety and Research,
Japan, and a grant-in-aid from the Ministry of Education, Culture,
Sports, Science and Technology.
References
[1] Prescott, J.C. and Blackburn, E.H. (1999) Curr. Opin. Genet.
Dev. 9, 368^373.
[2] Shay, J.W. and Bacchetti, S. (1997) Eur. J. Cancer 33, 787^791.
[3] Meyerson, M. et al. (1997) Cell 90, 785^795.
[4] Nakamura, T.M., Morin, G.B., Chapman, K.B., Weinrich, S.L.,
Andrews, W.H., Lingner, J., Harley, C.B. and Cech, T.R. (1997)
Science 277, 955^959.
[5] Bodnar, A.G. et al. (1998) Science 279, 349^352.
[6] Weinrich, S.L. et al. (1997) Nat. Genet. 17, 498^502.
[7] Beattie, T.L., Zhou, W., Robinson, M.O. and Harrington, L.
(1998) Curr. Biol. 8, 177^180.
[8] Nakayama, J. et al. (1998) Nat. Genet. 18, 65^68.
[9] Wu, K.J., Grandori, C., Amacker, M., Simon-Vermot, N., Po-
lack, A., Lingner, J. and Dalla-Favera, R. (1999) Nat. Genet. 21,
220^224.
[10] Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J.,
Yutsudo, M. and Inoue, M. (1999) Cancer Res. 59, 551^557.
[11] Greenberg, R.A. et al. (1999) Oncogene 18, 1219^1226.
[12] Kyo, S., Takakura, M., Kanaya, T., Zhuo, W., Fujimoto, K.,
Nishio, Y., Orimo, A. and Inoue, M. (1999) Cancer Res. 59,
5917^5921.
[13] Kyo, S., Takakura, M., Taira, T., Kanaya, T., Itoh, H., Yutsudo,
M., Ariga, H. and Inoue, M. (2000) Nucleic Acids Res. 28, 669^
677.
[14] Fujimoto, K., Kyo, S., Takakura, M., Kanaya, T., Kitagawa, Y.,
Itoh, H., Takahashi, M. and Inoue, M. (2000) Nucleic Acids Res.
28, 2557^2562.
[15] Crowe, D.L., Nguyen, D.C., Tsang, K.J. and Kyo, S. (2001)
Nucleic Acids Res. 29, 2789^2794.
[16] Wang, J., Xie, L.Y., Allan, S., Beach, D. and Hannon, G.J.
(1998) Genes Dev. 12, 1769^1774.
[17] Cerni, C. (2000) Mutat. Res. 462, 31^47.
[18] Grandori, C., Cowley, S.M., James, L.P. and Eisenman, R.N.
(2000) Annu. Rev. Cell. Dev. Biol. 16, 653^699.
[19] Greider, C.W. (1998) Proc. Natl. Acad. Sci. USA 95, 90^92.
[20] Sawadogo, M., Van Dyke, M.W., Gregor, P.D. and Roeder,
R.G. (1988) J. Biol. Chem. 263, 11985^11993.
[21] Roy, A.L., Meisterernst, M., Pognonec, P. and Roeder, R.G.
(1991) Nature 354, 245^248.
[22] Liu, J., Antaya, M., Boerboom, D., Lussier, J.G., Silversides,
D.W. and Sirois, J. (1999) J. Biol. Chem. 274, 35037^35045.
[23] Sirito, M., Lin, Q., Maity, T. and Sawadogo, M. (1994) Nucleic
Acids Res. 22, 427^433.
[24] Luo, X. and Sawadogo, M. (1996) Mol. Cell. Biol. 16, 1367^
1375.
[25] Viollet, B., Lefrancois-Martinez, A.M., Henrion, A., Kahn, A.,
Raymondjean, M. and Martinez, A. (1996) J. Biol. Chem. 271,
1405^1415.
[26] Tatematsu, K., Nakayama, J., Danbara, M., Shionoya, S., Sato,
H., Omine, M. and Ishikawa, F. (1996) Oncogene 13, 2265^2274.
[27] Dignam, J.D. (1990) Methods Enzymol. 182, 194^203.
[28] Kosciolek, B.A. and Rowley, P.T. (1999) Leuk. Res. 23, 1097^
1103.
[29] Liu, K., Schoonmaker, M.M., Levine, B.L., June, C.H., Hodes,
R.J. and Weng, N.P. (1999) Proc. Natl. Acad. Sci. USA 96,
5147^5152.
[30] Rufer, N., Migliaccio, M., Antonchuk, J., Humphries, R.K.,
Roosnek, E. and Lansdorp, P.M. (2001) Blood 98, 597^603.
[31] Wen, J., Cong, Y.S. and Bacchetti, S. (1998) Hum. Mol. Genet.
7, 1137^1141.
[32] Reed, J.C., Nowell, P.C. and Hoover, R.G. (1985) Proc. Natl.
Acad. Sci. USA 82, 4221^4224.
[33] Hu, B.T. and Insel, R.A. (1999) Eur. J. Immunol. 29, 3745^3753.
[34] Klingelhutz, A.J., Foster, S.A. and McDougall, J.K. (1996) Na-
ture 380, 79^82.
[35] Gewin, L. and Galloway, D.A. (2001) J. Virol. 75, 7198^7201.
[36] Boyd, K.E. and Farnham, P.J. (1999) Mol. Cell. Biol. 19, 8393^
8399.
FEBS 26113 27-5-02
M. Yago et al./FEBS Letters 520 (2002) 40^4646
